Educational CME accredited programme

Sunday 26 May


Can new therapies alter the course of ASCVD?

Need for speed-impact of lipid lowering therapy on plaque
Steve Nicholls, Australia
How to identify the patient about to have an ACS?
Pasquale Filardi, Italy
Trajectory of CV risk for ASCVD patients-how can we change it?
Julia Brandts, UK

Combatting the triple threat of CVD,DM and CKD

Mitigating the risk of ASCVD in diabetes with GLP-1RA- How do they work and who benefits?
Andre J Scheen, Belgium
The Holy Grail- Weight management therapy to reduce CV events-from diet, drugs or surgery
Nick Finer, UK
New horizons in the management of diabetic kidney disease
Janaka Karalliedde, UK

Time to act: Real world solutions for LDL-C management

Get it right the first time: Approach to managing post acute coronary syndromes LDL-C
Pasquale Filardi, Italy
Does fire and forget get to goal?
Erik Stroes, The Netherlands
Addressing common myths of low LDL-C: What did we learn from FOURIER-OLE and real world data?
Robert Giugliano, USA

Monday 27 May


Translating scientific evidence into daily practice in lipid lowering therapy

Lipid lowering therapy in Europe: Where do we stand?
Carlos Aguiar, Portugal
When and how to start lipid lowering therapy: New trials, new learnings
Kausik Ray, UK

EAS have independently organised all matters related to this programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.